Tipapkinogene sovacivec

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameTipapkinogene sovacivec
Drug Alias NameMVA-HPV-IL2 vaccinetipapkinogen sovacivecR-3484RG-3484TG-4001 +[6] 
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Recombinant vector vaccine
Mechanisms of ActionImmunostimulantsT lymphocytes stimulants
TargetsNot applicable
Therapy Area/IndicationsPenile NeoplasmsVulvar NeoplasmsUterine Cervical Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesPuerto Rico +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesPfizer IncTransgene SaMerck & Co Inc
China Registration ClassN/A

Develop Information

Active CompaniesTransgene SaPfizer Inc
Inactive CompaniesF. Hoffmann-La Roche Ltd
Active IndicationsPenile NeoplasmsVulvar NeoplasmsUterine Cervical Neoplasms +[4] 
Inactive IndicationsCervical Intraepithelial NeoplasiaNeoplasms

Other Information

ATC CodeN/A
Related LinksKEGG